XTX Topco Ltd Has $72,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

XTX Topco Ltd cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 87.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,782 shares of the company’s stock after selling 223,267 shares during the period. XTX Topco Ltd’s holdings in Xeris Biopharma were worth $72,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Simplicity Wealth LLC acquired a new position in Xeris Biopharma in the 2nd quarter valued at $27,000. Bayesian Capital Management LP acquired a new position in shares of Xeris Biopharma in the 1st quarter valued at approximately $37,000. Allspring Global Investments Holdings LLC boosted its position in shares of Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after acquiring an additional 15,929 shares in the last quarter. Quarry LP bought a new position in Xeris Biopharma in the fourth quarter valued at approximately $47,000. Finally, Eagle Asset Management Inc. acquired a new position in Xeris Biopharma during the fourth quarter valued at approximately $48,000. 42.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Xeris Biopharma in a research note on Thursday, August 15th.

Xeris Biopharma Trading Down 2.1 %

Shares of XERS stock opened at $2.79 on Wednesday. The firm has a market capitalization of $413.63 million, a price-to-earnings ratio of -5.94 and a beta of 2.76. The business’s 50-day moving average price is $2.66 and its 200-day moving average price is $2.28. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.46 and a 12 month high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $48.07 million for the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same period in the previous year, the firm posted ($0.14) EPS. On average, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.